FindTrial
Sign In

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9

Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00000274
Enrollment
60
Registered
1999-09-21
Start date
1997-03-31
Completion date
1999-05-31
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cocaine-Related Disorders, Substance-Related Disorders

Keywords

cocaine dependence

Brief summary

The purpose of this study is to evaluate the safety and efficacy of flupenthixol and haloperidol for cocaine dependence in individuals with schizophrenia/schizoaffective illness.

Interventions

DRUGFlupenthixol

Sponsors

New York State Psychiatric Institute
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Primary purpose
TREATMENT

Eligibility

Sex/Gender
ALL
Age
18 Years to 45 Years
Healthy volunteers
No

Inclusion criteria

Please contact site for information.

Design outcomes

Primary

MeasureTime frame
Side effects—
Drug use—
Psychiatric symptoms—
Cocaine craving—

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026